ECOG- Frequently Asked Questions about the Prostate Cancer Study (E1899)

Follow the links below to view an announcement and a handout answering frequently asked questions about the E1899 ECOG Prostate Cancer Study. This is a "Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with A Rising PSA After Hormonal Therapy for Prostate Cancer".

Frequently Asked Questions about the Prostate Cancer Study

The document is in Adobe Acrobat format. If you do not already have Adobe Acrobat Reader running on your computer you can download this software free of charge from the Adobe web site.

Next topic